Charité - Universitätsmedizin Berlin

Quantitative susceptibility mapping across two clinical field strengths: Contrast-to-noise ratio enhancement at 1.5T (2018) Ippoliti M, Adams LC, Winfried B, Hamm B, Spincemaille P, Wang Y, Makowski MR Journal article Non-alcoholic fatty liver disease in underweight patients with inflammatory bowel disease: A case-control study (2018) Adams LC, Luebbe F, Bressem K, Wagner M, Hamm B, Makowski MR Journal article Prolonged unconsciousness after applying caudal anaesthesia Prolongierte Bewusstlosigkeit nach Anlage einer Kaudalanästhesie (2018) Schulte E, Koch S, Schröder JT, Tietze A, Binscheck-Domass T, Kramer S, Rothe K, Francis RCE Journal article Confocal Raman microscopy combined with optical clearing for identification of inks in multicolored tattooed skin: In vivo (2018) Darvin ME, Schleusener J, Parenz F, Seidel O, Krafft C, Popp J, Lademann J Journal article Ga-68-PSMA PET/CT in treatment-naïve patients with prostate cancer: Which clinical parameters and risk stratification systems best predict PSMA-positive metastases? (2018) Rogasch JM, Cash H, Zschaeck S, Elezkurtaj S, Brenner W, Hamm B, Makowski M, et al. Journal article Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC) (2018) Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, et al. Conference contribution Evaluation of the MammaTyperVR as a molecular predictor for pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) and outcome in patients with different breast cancer (BC) subtypes (2018) Fasching P, Laible M, Weber KE, Wirtz RM, Denkert C, Schlombs K, Schmatloch S, et al. Conference contribution Validation of the MammaTyper (R) pathological complete response (pCR)-score as a predictor for response after neoadjuvant chemotherapy (NACT) in patients with early breast cancer (BC) (2018) Fasching P, Laible M, Weber KE, Wirtz RM, Denkert C, Schlombs K, Schmatloch S, et al. Conference contribution Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study (2018) Pohl E, Schneeweiss A, Hauke J, Moebus V, Furlanetto J, Denkert C, Fasching P, et al. Conference contribution Real-world effectiveness of ribociclib 1 aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: The RIBANNA study (2018) Fasching P, Decker T, Guderian G, Heim J, Jackisch C, Lueck HJ, Lueftner D, et al. Conference contribution